5.73

2.14% 0.12

Pre-market: 5.70 -0.03 -0.52%

Solid Biosciences Inc (SLDB)

Overview News Price History Option Chain Financials Why SLDB Down? Discussions Forecast Stock Split

Solid Biosciences Inc stock is traded at $5.73, with a volume of 1.27M. It is up +2.14% in the last 24 hours and up +62.32% over the past month. Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Previous Close:

$5.61

Open:

$5.6

24h Volume:

1.27M

Relative Volume:

0.61

Market Cap:

$444.03M

Revenue:

$14.79M

Net Income/Loss:

$-102.44M

P/E Ratio:

-1.8849

EPS:

-3.04

Net Cash Flow:

$-91.73M

1W Performance:

-0.52%

1M Performance:

+62.32%

6M Performance:

-25.78%

1Y Performance:

-49.74%

1-Day Range:

$5.5419

$5.85

1-Week Range:

$4.87

$5.85

52-Week Range:

$2.88

$15.05

Solid Biosciences Inc Stock (SLDB) Company Profile

Name

Solid Biosciences Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

617-337-4680

Address

500 RUTHERFORD AVENUE, CHARLESTOWN, MA

Employee

100

Twitter

@SolidBioDMD

Next Earnings Date

2024-11-06

Latest SEC Filings

SLDB's Discussions on Twitter

Compare SLDB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLDB Solid Biosciences Inc	5.73	444.03M	14.79M	-102.44M	-91.73M	-3.04
VRTX Vertex Pharmaceuticals Inc	495.42	127.22B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	689.50	75.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.45	35.94B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.43	31.38B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.84	26.84B	3.32B	-860.46M	-1.04B	-8.32

Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-25	Initiated	Truist	Buy
Dec-13-24	Initiated	Wedbush	Outperform
Dec-10-24	Initiated	JMP Securities	Mkt Outperform
Jul-15-24	Upgrade	JP Morgan	Neutral → Overweight
Jun-24-24	Upgrade	Leerink Partners	Market Perform → Outperform
May-31-24	Resumed	Piper Sandler	Overweight
Mar-28-24	Initiated	William Blair	Outperform
Mar-15-24	Initiated	Citigroup	Buy
Mar-14-24	Upgrade	Piper Sandler	Neutral → Overweight
Dec-08-23	Initiated	H.C. Wainwright	Buy
Jul-12-21	Initiated	Piper Sandler	Neutral
May-27-21	Initiated	Jefferies	Buy
Mar-16-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-09-21	Initiated	Barclays	Overweight
Jan-08-21	Upgrade	Credit Suisse	Underperform → Neutral
Jul-28-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-07-20	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-19	Initiated	Evercore ISI	Outperform
Aug-29-19	Downgrade	Citigroup	Neutral → Sell
Aug-19-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Aug-16-19	Upgrade	Chardan Capital Markets	Neutral → Buy
May-14-19	Downgrade	Credit Suisse	Neutral → Underperform
May-14-19	Downgrade	Goldman	Neutral → Sell
Feb-08-19	Upgrade	Citigroup	Sell → Neutral
Feb-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-18	Initiated	Citigroup	Sell
Sep-06-18	Initiated	Credit Suisse	Neutral

View All

Solid Biosciences Inc Stock (SLDB) Latest News

02:20 AM

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewswire

Mar 12, 2025

Breakthrough DMD Gene Therapy Results: Solid Bio Reveals INSPIRE Trial Data at Major Conference - StockTitan

Mar 12, 2025

Mar 11, 2025

Solid Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 11, 2025

Solid Biosciences Inc. (NASDAQ:SLDB) Shares Acquired by Rhumbline Advisers - Defense World

Mar 11, 2025

HC Wainwright Issues Positive Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price - Defense World

Mar 11, 2025

Mar 10, 2025

Solid Biosciences shares leap on raised price target to $20 By Investing.com - Investing.com Canada

Mar 10, 2025

Solid Biosciences price target raised to $20 from $16 at H.C. Wainwright - TipRanks

Mar 10, 2025

FY2026 Earnings Forecast for SLDB Issued By William Blair - Defense World

Mar 10, 2025

Mar 09, 2025

Chardan Capital Reaffirms “Buy” Rating for Solid Biosciences (NASDAQ:SLDB) - Defense World

Mar 09, 2025

Mar 07, 2025

SLDB Stock Rallies 60% in a Month: Here's What You Should Know - MSN

Mar 07, 2025

Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade - Yahoo Finance

Mar 07, 2025

Solid Biosciences Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView

Mar 07, 2025

Solid Biosciences stock target holds at $15 on therapy optimism - Investing.com

Mar 07, 2025

Solid Biosciences: Promising Gene Therapy Advancements and Strategic Pipeline Expansion Justify Buy Rating - TipRanks

Mar 07, 2025

Solid Biosciences: Positive DMD Program Developments and Strong Financial Position Justify Buy Rating - TipRanks

Mar 07, 2025

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire

Mar 07, 2025

Mar 06, 2025